Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)
Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)
复制标题
DOI：
10.1016/j.intimp.2020.106198
复制
发表时间：
2020-03-01
影响因子：
5.6
通讯作者：
Ke, Zunfu
中科院分区：
文献类型：
--
作者：
Sun, Yu;Luo, Jiping;Ke, Zunfu
CD 155与其高亲和力配体TIGIT之间的相互作用在各种实体瘤中被越来越多地研究。然而，CD 155和TIGIT在肺腺癌（LUAD）中的预后意义仍不清楚。本研究应用免疫组织化学方法检测334例LUAD患者的CD 155和TIGIT的表达。对5对原发LUAD及癌旁正常肺组织进行免疫印迹分析。我们的研究结果表明，CD 155和TIGIT在LUAD组织中过表达，并且异常过表达与不良临床结局密切相关（P < 0.01）。多变量模型还显示，CD 155表达是LUAD的独立危险因素（RR，1.34; P = 0.036）。此外，高表达⑶ 155和TIGIT的患者同时呈现较短的总生存期（OS）（P < 0.01）和无进展生存期（PFS）（P < 0.01）。这些发现表明，CD 155和TIGIT可以组成一个预测临床结果的辅助工具，从而有助于LUAD的个性化医疗护理。
The interaction between CD155 and its high-affinity ligand TIGIT is being increasingly investigated in various solid tumors. However, the prognostic significance of CD155 and TIGIT in lung adenocarcinoma (LUAD) remains unclear. In this study, immunohistochemistry was applied in 334 LUAD cases to evaluate the expression of CD155 and TIGIT. Western blotting was conducted in 5 paired primary LUAD and adjacent normal lung tissues. Our results reveal that CD155 and TIGIT are overexpressed in LUAD tissues and that aberrant overexpression is closely correlated with poor clinical outcomes (P < 0.01). The multivariate model also shows that CD155 expression is an independent risk factor for LUAD (RR, 1.34; P = 0.036). Moreover, patients expressing high CD155 and TIGIT simultaneously presented shorter overall survival (OS) (P < 0.01) and progression-free survival (PFS) (P < 0.01). These findings suggest that CD155 and TIGIT can make up a prognosticating tool to predict clinical outcomes, thereby contributing to personalized medical care in LUAD.